- Details
- Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the publication on genomic classifier performance in intermediate-risk prostate cancer, focusing on the results of the NRG Oncology/RTOG 01-26 randomized Phase 3 trial. The study explores the use of the Decipher 22-gene genomic classifier in risk stratification, outperforming other common risk classification systems for prostatectomy and pre-treatment biopsy...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a head-to-head comparison of 68 Gallium-NODAGA-JR11 and 68 Gallium-DOTATATE PET/CT in patients with metastatic, well-differentiated neuroendocrine tumors. The study they refer to is a two-center, prospective analysis, which included 48 out of 100 planned patients. The conversation highlights the limited performance characteristics of current somatostatin rec...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the cardiovascular safety of testosterone replacement therapy, specifically the TRAVERSE trial's findings. This Phase 4 randomized trial was designed to determine the effects of testosterone replacement therapy on the incidence of major adverse cardiovascular events in middle-aged and older men with hypogonadism and either preexisting or high risk of cardiov...
|
- Details
- Zach Klaassen is joined by Rashid Sayyid to analyze the ACDC-RP Phase II Trial concerning neoadjuvant therapy in high-risk prostate cancer patients. The trial focuses on the combination of cabazitaxel, abiraterone, and leuprolide, examining the high treatment failure rates and mortality in this patient group. The discussion details the trial's design, methodology, endpoints, and safety assessments...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss an artificial intelligence (AI) predictive model for hormone therapy use in prostate cancer developed by Dr. Daniel Spratt. The model addresses the issue of unnecessary Androgen Deprivation Therapy (ADT), a treatment with severe side effects, currently recommended to varying extents based on National Comprehensive Cancer Network (NCCN) risk groups. The AI mo...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a study published in the Annals of Oncology, which delves into the clinical and transcriptomic heterogeneity of metastatic castration-sensitive prostate cancer (mCSPC). The study reveals important differences in patient prognosis based on disease volume and timing of metastases, with the worst prognosis found in synchronous high volume patients. The importan...
|
- Details
- Rashid Sayyid and Zach Klaassen review a study concerning AR and PI3K genomic profiling of cell-free DNA to identify poor responders to Lutetium-177-PSMA among mCRPC patients. This therapy is approved for patients whose disease has progressed following prior chemotherapy and androgen receptor signaling inhibitor, based on two Randomized Control Trials (RCTs): VISION and TheraP. These RCTs, however...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the development and validation of a multi-institutional nomogram for predicting outcomes of PSMA-PET-Based Salvage Radiotherapy in recurrent Prostate Cancer cases. Noting that 30-50% of high-risk patients experience biochemical failure within five years of radical prostatectomy, Drs. Sayyid and Klaassen highlight the increasing use of PSMA-PET/CT for staging...
|
- Details
- Rashid Sayyid and Zach Klaassen engage in a discussion about a Journal of Clinical Oncology publication. The study validates a prognostic model for overall survival in men with chemotherapy naive mCRPC, showcasing its overall predictive measure with a time-dependent area under the curve of 0.75. They emphasize the model's applicability, initially developed by Dr. Susan Halabi, that incorporates ro...
|
